Skip to content

Study · Measured the body's own peptide · 2012

4 results

Contribution of cerebrospinal fluid thymosin β4 levels to the clinical differentiation of Creutzfeldt-Jakob disease.

Le Pera M, Urso E, Sprovieri T, Bossio S, Aguglia U, Manna I, Cupidi C, Ferraro T, Gambardella A, Qualtieri A, Quattrone A

Archives of neurology1 Jul 2012Cited by 10 (Europe PMC)

PMID22431836 (opens in a new tab)DOI10.1001/archneurol.2011.3558 (opens in a new tab)PepBankPUB-22431836
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In cerebrospinal fluid, Tβ4 levels were markedly higher in patients with Creutzfeldt-Jakob disease than in patients with Alzheimer disease.

    In plain wordsIn patients with Creutzfeldt-Jakob disease, the body's own Tβ4 in spinal fluid was linked to higher levels than in Alzheimer disease.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCSF Tβ4 in CJD versus Alzheimer disease
    Study

    n = 39

    Comparator
    Probable Alzheimer disease
    Outcome group
    Endogenous peptide levels · Nervous system and cognition

    Source sentences

    Summary
    The thymosin β4 cerebrospinal fluid levels appeared to be markedly increased in CJD samples compared with frontotemporal cases (P = 10(-7)) and patients with Alzheimer disease (P = 10(-7))
    2 context sentences
    Summary · context
    Cerebrospinal fluid analysis was performed on 21 patients with neuropathologically confirmed CJD; 15 patients with frontotemporal dementia; 18 patients with probable Alzheimer disease; and 9 patients with a rapid-onset progressive dementia.
    Summary · context
    A non-cognitively impaired control group consisted of 25 individuals without CJD or dementia.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In cerebrospinal fluid, Tβ4 levels were markedly higher in patients with Creutzfeldt-Jakob disease than in patients with frontotemporal dementia.

    In plain wordsIn patients with Creutzfeldt-Jakob disease, the body's own Tβ4 in spinal fluid was linked to higher levels than in frontotemporal dementia.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCSF Tβ4 in CJD versus frontotemporal dementia
    Study

    n = 36

    Comparator
    Frontotemporal dementia
    Outcome group
    Endogenous peptide levels · Nervous system and cognition

    Source sentences

    Summary
    The thymosin β4 cerebrospinal fluid levels appeared to be markedly increased in CJD samples compared with frontotemporal cases (P = 10(-7))
    2 context sentences
    Summary · context
    Cerebrospinal fluid analysis was performed on 21 patients with neuropathologically confirmed CJD; 15 patients with frontotemporal dementia; 18 patients with probable Alzheimer disease; and 9 patients with a rapid-onset progressive dementia.
    Summary · context
    A non-cognitively impaired control group consisted of 25 individuals without CJD or dementia.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In cerebrospinal fluid, Tβ4 levels were higher in Creutzfeldt-Jakob disease than in rapid-onset progressive dementia, with a lower significance.

    In plain wordsIn patients with Creutzfeldt-Jakob disease, the body's own Tβ4 in spinal fluid was linked to higher levels than in rapid-onset dementia.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCSF Tβ4 in CJD versus rapid-onset progressive dementia
    Study

    n = 30

    Comparator
    Rapid-onset progressive dementia
    Outcome group
    Endogenous peptide levels · Nervous system and cognition

    Source sentences

    Summary
    A lower significance was observed vs the group with rapid-onset progressive dementia (P = .0004).
    2 context sentences
    Summary · context
    Cerebrospinal fluid analysis was performed on 21 patients with neuropathologically confirmed CJD; 15 patients with frontotemporal dementia; 18 patients with probable Alzheimer disease; and 9 patients with a rapid-onset progressive dementia.
    Summary · context
    A non-cognitively impaired control group consisted of 25 individuals without CJD or dementia.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    At a cutoff of 1.2% Tβ4 relative peak area, cerebrospinal fluid Tβ4 gave 100% sensitivity and 98.5% specificity for Creutzfeldt-Jakob disease.

    In plain wordsA spinal fluid test of the body's own Tβ4 picked out Creutzfeldt-Jakob disease with 100% sensitivity and 98.5% specificity at one cutoff.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableDiagnostic sensitivity and specificity of CSF Tβ4 for CJD
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Nervous system and cognition

    Measurements

    Cutoff relative peak area
    1.2%
    Tβ4 MS signal
    Sensitivity
    100%
    CJD
    Specificity
    98.5%
    CJD

    Source sentences

    Summary
    Thus, at a cutoff value of 1.2% of the thymosin β4 relative peak area, we estimated 100% sensitivity with 98.5% specificity.
    2 context sentences
    Summary · context
    Cerebrospinal fluid analysis was performed on 21 patients with neuropathologically confirmed CJD; 15 patients with frontotemporal dementia; 18 patients with probable Alzheimer disease; and 9 patients with a rapid-onset progressive dementia.
    Summary · context
    A non-cognitively impaired control group consisted of 25 individuals without CJD or dementia.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.